Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Clin Cancer Res. 2017 Sep 12;24(5):1002–1010. doi: 10.1158/1078-0432.CCR-17-0539

Figure 1.

Figure 1

Comparing the immune microenvironment in Hodgkin lymphoma and multiple myeloma.

AP-1 = activating protein-1, B2m = beta-2 microglobulin, CTL = cytotoxic T lymphocyte, EBV = Epstein Barr Virus, IFNGR = Interferon gamma receptor, IL-2 = Interleukin 2, IL-12: Interleukin 12, IL-10: Interleukin-10, IL-6: Interleukin 6, HRS = Hodgkin Reed Sternberg Cell, JAK2 = Janus Kinase 2, AP1, LMP1 = Latent membrane protein-1PD-1= Programmed cell death 1, PD-L1 = Programmed cell death ligand 1, MDSC = Myeloid-derived suppressor cells, aPD-1 = anti-PD-1, MM-PC = Multiple Myeloma clonal plasma cell, TCR = T cell receptor, TGFb = transforming growth factor beta, TNF-a = tumor necrosis factor alpha. Treg = regulatory T cell, MHC-I = major histocompatibility complex I, MHC-II major histocompatibility complex II.